ArticleFrontiers in bioengineering and biotechnology2025
Quantitative absorptive micro-sampling for decentralized monitoring of insulin-like growth factor 1.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study establishes a novel quantitative acoustic mass spectrometry (QAMS) methodology for insulin-like growth factor 1 (IGF-1) detection. Methods: Chromatographic separation utilized a Peptide C18 column (1.8 μm, 50 mm) with 0.1% formic acid/acetonitrile gradient elution, coupled to tandem mass spectrometry operated in scheduled multiple reaction monitoring (sMRM) mode. Results: The method demonstrated a lower limit of quantification (LOQ) of 10 ng/mL with linear dynamic range spanning 10-500 ng/mL. Comparative analysis of 74 paired plasma specimens revealed strong inter-matrix correlation with quantifiable bias. Discussion: These advancements position QAMS- as a robust tool for decentralized IGF-1 monitoring, particularly valuable in pediatric growth disorder studies and resource-limited settings. Longitudinal stability validation and isoform differentiation remain focal points for future optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.